Last reviewed · How we verify
Subanesthetic dose of esketamine — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Subanesthetic dose of esketamine (Subanesthetic dose of esketamine) — bo xu.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Subanesthetic dose of esketamine TARGET | Subanesthetic dose of esketamine | bo xu | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Subanesthetic dose of esketamine CI watch — RSS
- Subanesthetic dose of esketamine CI watch — Atom
- Subanesthetic dose of esketamine CI watch — JSON
- Subanesthetic dose of esketamine alone — RSS
Cite this brief
Drug Landscape (2026). Subanesthetic dose of esketamine — Competitive Intelligence Brief. https://druglandscape.com/ci/subanesthetic-dose-of-esketamine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab